One-Liner
Cloud-based autonomous MRI progression reader sold as a fixed-price endpoint read service to multiple sclerosis clinical trial sponsors.
AI Thinking Process
Scale Shift: Hospital-grade neuroradiology workflow → cloud-based autonomous MRI progression reader for pharma sponsor trials. Fenebrutinib BTK H1 2026 readout opens MS trial wave.
Icometrix (EUR 35M), Neuropoly, QMENTA (post-acquisition), Neurophet. Space competitive. CRO-as-a-service angle: Icometrix already offers clinical trial endpoint reads as a service. Bioclinica also.
KILLED: Icometrix + IXICO + Bioclinica fully occupy this lane with funded multi-year positions. New entrant needs 10x technical advantage which is hard to claim in a category with 3 funded competitors already using AI.
Kill Reason
Three funded incumbents — Icometrix (EUR 35M raised), IXICO, and Bioclinica — fully occupy the CRO-as-a-service lane for neuroradiology trial endpoint reads. New entrant would need a 10x technical advantage in a category with 3+ funded competitors already using AI.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.